AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin.

Gemtuzumab ozogamicin (GO), an immunoconjugate between an anti-CD33 antibody and a calicheamicin-γ(1) derivative, induces remissions and improves survival in a subset of patients with acute myeloid leukemia (AML). As the mechanisms underlying GO and calicheamicin-γ(1) resistance are incompletely und...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	David B Rosen, Kimberly H Harrington, James A Cordeiro, Ling Y Leung, Santosh Putta, Norman Lacayo, George S Laszlo, Chelsea J Gudgeon, Donna E Hogge, Rachael E Hawtin, Alessandra Cesano, Roland B Walter
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Public Library of Science (PLoS) 2013-01-01
Sarja:	PLoS ONE
Linkit:	https://doi.org/10.1371/journal.pone.0053518
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!